NCT05023811

A Study of the ADME of [14C]RIST4721 in Healthy Male Subjects

A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]RIST4721 Following a Single Oral Dose to Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Aristea Therapeutics, Inc. · Industry
• Sex: Male
• Age: 30 Years – 65 Years
• Healthy volunteers: Accepted

Summary

A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of \[14C\]RIST4721 Following a Single Oral Dose to Healthy Male Subjects

Conditions

• Healthy
• ADME

Interventions

Type	Name	Description
DRUG	[14C]RIST4271	\[14C\]RIST4271 oral solution

Timeline

• Start date: 2021-08-11
• Primary completion: 2021-09-15
• Completion: 2021-09-15
• First posted: 2021-08-27
• Last updated: 2022-01-10

Locations

1 site across 1 country: United Kingdom

Regulatory

• FDA-regulated drug study